Webinar Overview: Managing Donor Variability and Using Ex Vivo Testing to Strengthen CAR-T Therapy Development
The development and efficiency of your cell therapy, including CAR therapies, can be influenced by the variability of cellular starting material and differences between donors. Therefore, identifying an effective strategy for donor management and using robust preclinical efficacy testing models can mitigate risk and even get your cell therapy to market faster.
View this webinar as we examine data highlighting the importance of utilizing highly characterized and recallable donors to ensure consistency in your therapy development. We’ll also discuss a unique ex vivo efficacy testing platform engineered by Xsphera Biosciences using microfluidics-based technology, enabling dynamic analysis of a CAR-T cell therapy activity and kinetics.
Key Takeaways for CAR-T Development
- Donor management strategies to improve cell therapy outcomes
- The impact of source material variability on downstream cell therapy efficiency
- Dynamic ex vivo preclinical efficacy testing models
- The impact of differential gene expression between donors on cell therapy potency
Webinar Presenters
Raluca Dumitru, MD, PhD
Scientific Sales Director - Cell Solutions
Charles River
Aaron Goldman, PhD
Faculty and Instructor in Medicine
Harvard Medical School